These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 950543)

  • 21. The relationship of plasma prolactin to 17-B oestradiol in women with tumours of the breast.
    Jones MK; Ramsay ID; Collins WP; Dyer GI
    Eur J Cancer (1965); 1977 Oct; 13(10):1109-12. PubMed ID: 923610
    [No Abstract]   [Full Text] [Related]  

  • 22. [Proceedings: Role of prolactin in breast cancer. (2)].
    Daigo K; Kato Y; Fujiwara T; Chihara K; Imura H
    Nihon Naibunpi Gakkai Zasshi; 1974 Feb; 50(2):507. PubMed ID: 4476535
    [No Abstract]   [Full Text] [Related]  

  • 23. [Changes in prolactin plasma levels in relation to menopausal status in primary breast carcinoma].
    Pavić S; Pavić Z
    Med Pregl; 1995; 48(5-6):159-61. PubMed ID: 7565335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Plasma-prolactin concentrations in breast cancer at various stages, in mastopathy and other malignant tumors].
    Holtkamp W; von Heyden D; Rauschecker H; Nagel GA
    Schweiz Med Wochenschr; 1983 Oct; 113(41):1513-20. PubMed ID: 6635641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circadian mesor-hyperprolactinemia in fibrocystic mastopathy.
    Tarquini B; Gheri R; Romano S; Costa A; Cagnoni M; Lee JK; Halberg F
    Am J Med; 1979 Feb; 66(2):229-37. PubMed ID: 425966
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of fibrocystic disease of the breast with a prolactin inhibitor: 2-Br-alpha-ergocryptine (CB-154).
    Martin-Comin J; Pujol-Amat P; Cararach V; Davi E; Robyn C
    Obstet Gynecol; 1976 Dec; 48(6):703-6. PubMed ID: 1036613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum hormones in human breast cancer subjects.
    Krishnamoorthy G; Govindarajulu P; Ramalingam V
    Neoplasma; 1989; 36(2):221-31. PubMed ID: 2497392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum oestradiol-17 beta in women with benign and malignant breast disease.
    England PC; Skinner LG; Cottrell KM; Sellwood RA
    Br J Cancer; 1974 Dec; 30(6):571-6. PubMed ID: 4447785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Permanent alterations induced in plasma prolactin and estrogen receptor concentration in benign and malignant tissue of women who started oral contraceptive use at an early age.
    Olsson H; Lindahl B; Ranstam J; Borg A; Fernö M; Norgren A
    Anticancer Res; 1987; 7(4B):853-6. PubMed ID: 3674773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum hormones and lipoproteins in benign breast disease.
    Sundaram GS; London R; Margolis S; Wenk R; Lustgarten J; Nair PP; Goldstein P
    Cancer Res; 1981 Sep; 41(9 Pt 2):3814-6. PubMed ID: 6790170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Evaluation of the new marker CA 549 versus CA 15-3 in neoplastic and non-neoplastic disease of the breast].
    Di Seri M; Manna A; Sciò M; Marchei GG; De Benedetto A; Reale MG
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):49. PubMed ID: 2092149
    [No Abstract]   [Full Text] [Related]  

  • 32. Measurement of prostate-specific antigen in detection of benign or malignant breast disease in women.
    Romppanen J; Keskikuru R; Kataja V; Eskelinen M; Kosma VM; Savolainen K; Uusitupa M; Mononen I
    Br J Cancer; 1999 Mar; 79(9-10):1583-7. PubMed ID: 10188910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A correlation of erythrocyte sedimentation and plasma carcinoembryonic antigen in fibrocystic disease and carcinoma of the breast.
    Thynne GS; Greening WP
    Clin Oncol; 1980 Dec; 6(4):317-21. PubMed ID: 7460405
    [No Abstract]   [Full Text] [Related]  

  • 34. [Nipple discharge: differential diagnostic considerations].
    Räber G; Schneider HP
    Ther Umsch; 1993 May; 50(5):286-90. PubMed ID: 8378883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Possibility of using tumor markers, pituitary gonadotropic hormones and prolactin in the diagnosis of breast cancer].
    Korolev VI; Skliar SIu; Chebotareva ED; Akimova RN
    Vopr Onkol; 1986; 32(11):55-9. PubMed ID: 3788082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Super-sensitive prostate-specific antigen (PSA) in serum of women with benign breast disease or breast cancer.
    Hautmann S; Huland E; Grupp C; Haese A; Huland H
    Anticancer Res; 2000; 20(3B):2151-4. PubMed ID: 10928169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Studies on the oxygen-binding properties of the blood in patients with malignant tumors].
    Kochetkova MK; Belousov AP; Epshteĭn IM
    Vopr Med Khim; 1969; 15(1):56-60. PubMed ID: 5822031
    [No Abstract]   [Full Text] [Related]  

  • 38. [Prolactin and its clinical importance].
    Vasiukova EA; Pisarskaia IV
    Klin Med (Mosk); 1982 Mar; 60(3):9-15. PubMed ID: 6123615
    [No Abstract]   [Full Text] [Related]  

  • 39. Breast cancer and benign breast disease patients evaluated in relation to oxidative stress.
    Seven A; Erbil Y; Seven R; Inci F; Gülyaşar T; Barutçu B; Candan G
    Cancer Biochem Biophys; 1998 Nov; 16(4):333-45. PubMed ID: 9925281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Plasma levels of prolactin in women with dysplasia and tumors of the breast (fibroadenoma and carcinoma of the breast)].
    Iturburu Belmonte IM; Basáñez Amuchastegui A; Jiménez Jiménez E; López de Tejada Cabeza I; Goicoechea García J; Méndez Martín J
    Rev Quir Esp; 1988; 15(1):17-21. PubMed ID: 3153353
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.